Human AML cell lines, U937 and MV4–11 (CRL-9591) were purchased from the ATCC (Manassas, Virginia, USA), MOLM-13 (DSMZ Cat# ACC-554) and OCI-AML3 (DSMZ Cat# ACC-582) cells were purchased from DSMZ (Brunswick, Lower Saxony, Germany) and maintained as described previously [25 (link)]. All cell lines were tested for Mycoplasma contamination using the MycoAlert Mycoplasma Detection Kit (Lonza) routinely. All experiments utilized logarithmically growing cells (3–4×105 cells/ml).
Venetoclax-resistant MV4–11 and MOLM-13 cells were obtained by culturing in the presence of increasing venetoclax (from 1nM to 1μM) concentrations over a period of 2 months.
Venetoclax was a gift from AbbVie (Chicago, IL, USA). INK128, AZD2014 was purchased from ChemieTek (Indianapolis, IN, USA). copanlisib was purchased from AdooQ (Irvine, CA, USA). MK2206 was purchased from MedChemExpress (Monmouth Junction, NJ, USA). Rapamycin was purchased from Cell Signaling (Danvers, MA, USA). All drugs were dissolved in DMSO, aliquoted, and stored at −80. Final DMSO concentrations did not exceed 0.1%.
Venetoclax-resistant MV4–11 and MOLM-13 cells were obtained by culturing in the presence of increasing venetoclax (from 1nM to 1μM) concentrations over a period of 2 months.
Venetoclax was a gift from AbbVie (Chicago, IL, USA). INK128, AZD2014 was purchased from ChemieTek (Indianapolis, IN, USA). copanlisib was purchased from AdooQ (Irvine, CA, USA). MK2206 was purchased from MedChemExpress (Monmouth Junction, NJ, USA). Rapamycin was purchased from Cell Signaling (Danvers, MA, USA). All drugs were dissolved in DMSO, aliquoted, and stored at −80. Final DMSO concentrations did not exceed 0.1%.
